Form 4: Denali Therapeutics Director Sells 92,500 Shares Under 10b5-1 Trading Plan

Steve E. Krognes, a director at Denali Therapeutics Inc., sold 92,500 shares of common stock on April 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 1, 2024, Steve E. Krognes, a director of Denali Therapeutics Inc. (DNLI), sold 92,500 shares of common stock.
• The sales were executed under a Rule 10b5-1 trading plan adopted on December 1, 2023.
• The weighted average sale price was $20.5, with prices ranging from $20.06 to $20.73 per share.
• Following the transaction, Krognes directly owns 47,341 shares, including 16,716 unvested RSUs.
• He also indirectly owns 850,000 shares through The Steve Edward Krognes Revocable Trust U/A DTD 01/25/2016, where he serves as trustee.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 trading plan. It doesn't necessarily indicate a positive or negative outlook on the company's future.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares at predetermined times and prices, avoiding accusations of trading on material non-public information. The market will often look at the ratio of insider sales to insider buys to determine sentiment.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates